RadNet (RDNT) Stock Overview
Provides outpatient diagnostic imaging services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
RDNT Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
RadNet, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.19 |
| 52 Week High | US$85.84 |
| 52 Week Low | US$50.76 |
| Beta | 1.43 |
| 1 Month Change | 4.98% |
| 3 Month Change | -16.95% |
| 1 Year Change | 2.03% |
| 3 Year Change | 110.00% |
| 5 Year Change | 148.78% |
| Change since IPO | 5,719.00% |
Recent News & Updates
Narrative Update • May 07
RDNT: Imaging Platform Execution And New Idaho Venture Will Support Future Earnings
Analysts have trimmed their fair value estimate for RadNet by $0.50 to $89.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E after recent Street research, including a lower $4 price target from B. Riley and an upgrade of Lumexa Imaging at Raymond James.Narrative Update • Apr 23
RDNT: Sector Sentiment Tailwinds Will Support Future Earnings Visibility
Analysts have trimmed their price target on RadNet by $2 to reflect slightly updated assumptions on fair value, future P/E and operating metrics, while incorporating recent Street research that highlights improved sentiment following the Raymond James upgrade of Lumexa Imaging. Analyst Commentary Bullish Takeaways Bullish analysts view the recent upgrade of Lumexa Imaging as a supportive read-through for sentiment around diagnostic imaging.Narrative Update • Apr 08
RDNT: Outpatient Imaging Shift Will Support Future Earnings Visibility
RadNet's analyst price target now stands at $92. Analysts cite outpatient diagnostic imaging growth drivers, Medicare reimbursement support, potential capital deployment, and an AI ramp as key reasons for maintaining this level.Recent updates
Narrative Update • May 07
RDNT: Imaging Platform Execution And New Idaho Venture Will Support Future Earnings
Analysts have trimmed their fair value estimate for RadNet by $0.50 to $89.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E after recent Street research, including a lower $4 price target from B. Riley and an upgrade of Lumexa Imaging at Raymond James.Narrative Update • Apr 23
RDNT: Sector Sentiment Tailwinds Will Support Future Earnings Visibility
Analysts have trimmed their price target on RadNet by $2 to reflect slightly updated assumptions on fair value, future P/E and operating metrics, while incorporating recent Street research that highlights improved sentiment following the Raymond James upgrade of Lumexa Imaging. Analyst Commentary Bullish Takeaways Bullish analysts view the recent upgrade of Lumexa Imaging as a supportive read-through for sentiment around diagnostic imaging.Narrative Update • Apr 08
RDNT: Outpatient Imaging Shift Will Support Future Earnings Visibility
RadNet's analyst price target now stands at $92. Analysts cite outpatient diagnostic imaging growth drivers, Medicare reimbursement support, potential capital deployment, and an AI ramp as key reasons for maintaining this level.Narrative Update • Mar 25
RDNT: Outpatient Imaging Shift And AI Adoption Will Drive Future Upside
Analysts kept their $92 price target for RadNet unchanged, citing what they see as attractive long term growth drivers in outpatient diagnostic imaging, reasonable 2025 to 2028 company targets, supportive Medicare reimbursement trends, potential capital deployment benefits, and expected AI contributions. Analyst Commentary Bullish Takeaways Bullish analysts view outpatient diagnostic imaging as an attractive subsector, with hospital to outpatient shifts and growing demand for advanced imaging seen as key growth drivers that support RadNet's long term story and current valuation framework.Narrative Update • Mar 09
RDNT: Outpatient Imaging Shift And AI Ramp Will Support Future Upside
Analysts have raised their price target on RadNet from $91.75 to $92.38. The updated target reflects revised assumptions that incorporate higher projected revenue growth, a lower profit margin outlook, and a higher future P/E multiple supported by recent bullish Street research on outpatient imaging and AI benefits.Narrative Update • Feb 22
RDNT: Outpatient Imaging Shift And AI Adoption Will Support Future Upside
Analysts have trimmed their implied future P/E assumption for RadNet, leading to a slightly lower blended price target of about $97 vs. roughly $102 previously.Narrative Update • Feb 08
RDNT: Outpatient Imaging Shift And AI Breast Screening Will Support Upside
Analysts have raised their price target on RadNet to about $92, reflecting confidence in the outpatient diagnostic imaging segment and the company's 2025 to 2028 targets, including expected benefits from improved Medicare rates, potential capital deployment, and increasing AI contributions. Analyst Commentary Recent research reflects a generally constructive tone on RadNet, with several firms lifting price targets into the high US$80s to low US$90s range and highlighting both the core imaging business and longer term AI potential.Narrative Update • Jan 24
RDNT: Outpatient Imaging Shift And AI Breast Screening Will Drive Upside
Analysts lifted their price target on RadNet to about US$91.75 from roughly US$91.71, reflecting recent coverage that highlights outpatient imaging growth drivers, supportive Medicare reimbursement, capital deployment options, and potential contributions from artificial intelligence (AI). Analyst Commentary Recent Street research on RadNet focuses on outpatient imaging growth, long term targets and the role of AI and capital allocation in supporting the current valuation framework.Narrative Update • Jan 09
RDNT: Outpatient Imaging And AI Adoption Will Drive Future Outperformance
Analysts have raised their price target on RadNet to about US$92, citing what they view as reasonable 2025 to 2028 goals, supportive Medicare reimbursement trends, potential capital deployment upside, and growing contributions from AI and outpatient imaging demand. Analyst Commentary Recent research has focused on how RadNet's outpatient imaging footprint, AI initiatives, and long term financial targets could support its valuation and growth ambitions.Narrative Update • Dec 13
RDNT: Integrated Offerings And Margin Expansion Will Drive Future Outperformance
Analysts have modestly increased their price target on RadNet, citing stronger long term growth and margin expansion prospects highlighted at the recent investor day and reflected in updated fair value estimates rising from about $91.71 to roughly $92.50 per share, alongside reaffirmed expectations for double digit revenue growth and mid teens EBITDA expansion. Analyst Commentary Bullish analysts highlight that the updated 2028 targets for double digit revenue growth and margin expansion underpin a durable mid teens EBITDA growth profile, which they view as supportive of further multiple expansion from current levels.Narrative Update • Nov 28
RDNT: Sustained Demand And Integrated Offerings Will Drive Future Outperformance
Analysts have raised their price target for RadNet from approximately $87 to $93, citing higher revenue growth expectations and confidence in the company’s integrated offerings and sustained demand. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for RadNet, citing encouraging revenue growth expectations and confidence in the company’s ability to deliver sustained margin expansion.Analysis Article • Nov 14
Earnings Miss: RadNet, Inc. Missed EPS By 65% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that RadNet, Inc. ( NASDAQ:RDNT ) filed its third-quarter result this time last week...Narrative Update • Nov 13
RDNT: Momentum Will Accelerate From Surging Demand And Integrated Offerings
RadNet’s analyst price target has increased from $80.57 to $86.67. This reflects confidence from analysts who cite strong demand, integrated offerings, and positive industry momentum as key drivers.Narrative Update • Oct 30
RDNT: Imaging Center Demand And Digital Health Will Drive Measured Upside Potential
Analysts have increased their price target for RadNet from $74 to $81. They cite strong core imaging center demand and ongoing investments in digital health as key factors for the optimistic outlook.Narrative Update • Oct 15
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
RadNet's analyst price target has been raised from $79.29 to $80.57 per share. This change reflects analysts' optimism amid strong imaging center demand, ongoing digital health investments, and potential M&A opportunities.Narrative Update • Sep 19
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
RadNet’s consensus price target has risen to $79.29 as analysts cite robust imaging center demand, expanding service opportunities, strong digital health investments, and confidence in management’s strategic execution. Analyst Commentary Robust core imaging center demand trends indicate sustained growth potential.Analysis Article • Sep 12
RadNet (NASDAQ:RDNT) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Narrative Update • Sep 04
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
Driven by robust imaging center demand, growth opportunities, and strong digital health investments, RadNet’s consensus analyst price target held steady at $77.43. Analyst Commentary Robust core imaging center demand trends highlighted in recent management meetings.Seeking Alpha • Aug 18
RadNet: Bloated Capital Base Not Pulling Its Economic Weight (Rating Downgrade)
Summary I am downgrading RDNT stock to hold due to excessive capital requirements, bloated acquisitions, and declining returns on invested capital despite strong top-line growth. The valuation is stretched, with RadNet trading at 78x EBIT and >5x book value, while debt levels and working capital intensity have surged. Operating margins are compressing, free cash flow yields have turned negative, and acquisitions are not delivering sufficient economic returns. I will reconsider a more bullish stance only if RDNT demonstrates margin expansion, improved capital productivity, or stronger free cash flow generation. Read the full article on Seeking AlphaAnalysis Article • Jul 31
Some Confidence Is Lacking In RadNet, Inc.'s (NASDAQ:RDNT) P/S
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...Analysis Article • Jul 15
RadNet (NASDAQ:RDNT) May Have Issues Allocating Its Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analysis Article • Jun 10
We Think RadNet (NASDAQ:RDNT) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • May 15
RadNet, Inc. (NASDAQ:RDNT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Investors in RadNet, Inc. ( NASDAQ:RDNT ) had a good week, as its shares rose 9.8% to close at US$60.34 following the...Analysis Article • May 07
Is There An Opportunity With RadNet, Inc.'s (NASDAQ:RDNT) 37% Undervaluation?
Key Insights The projected fair value for RadNet is US$84.18 based on 2 Stage Free Cash Flow to Equity Current share...Analysis Article • Apr 24
Is RadNet, Inc. (NASDAQ:RDNT) Potentially Undervalued?
RadNet, Inc. ( NASDAQ:RDNT ), might not be a large cap stock, but it received a lot of attention from a substantial...Analysis Article • Apr 11
Returns On Capital Signal Tricky Times Ahead For RadNet (NASDAQ:RDNT)
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Seeking Alpha • Mar 11
RadNet: On The Sidelines For Now
Summary RDNT's stock performance has been lackluster, with only an 8.8% increase over the past year, currently trading at $50 per share. Despite decent fundamentals, including steady revenue growth and strong operating cash flow, RDNT faces risks from wage increases and weather-related disruptions. Recent market overreaction to temporary weather impacts presents a potential rebound opportunity, but the projected 8.6% return does not justify the investment risk. I rate RDNT as neutral due to uncertainties in revenue growth and bottom-line pressures, suggesting better opportunities elsewhere with more favorable risk-reward profiles. Read the full article on Seeking AlphaAnalysis Article • Feb 16
There's Reason For Concern Over RadNet, Inc.'s (NASDAQ:RDNT) Price
RadNet, Inc.'s ( NASDAQ:RDNT ) price-to-sales (or "P/S") ratio of 2.6x may not look like an appealing investment...Analysis Article • Jan 31
A Look At The Fair Value Of RadNet, Inc. (NASDAQ:RDNT)
Key Insights RadNet's estimated fair value is US$73.25 based on 2 Stage Free Cash Flow to Equity Current share price of...Analysis Article • Jan 16
Does RadNet (NASDAQ:RDNT) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Jan 01
Is It Time To Consider Buying RadNet, Inc. (NASDAQ:RDNT)?
RadNet, Inc. ( NASDAQ:RDNT ), might not be a large cap stock, but it received a lot of attention from a substantial...Analysis Article • Nov 12
There's Reason For Concern Over RadNet, Inc.'s (NASDAQ:RDNT) Massive 26% Price Jump
RadNet, Inc. ( NASDAQ:RDNT ) shares have continued their recent momentum with a 26% gain in the last month alone. The...Analysis Article • Oct 15
Here's What To Make Of RadNet's (NASDAQ:RDNT) Decelerating Rates Of Return
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Seeking Alpha • Oct 02
RadNet: Secular Tailwinds Underpinned By AI Monetization Prospects
Summary RadNet, the largest US diagnostic imaging operator, projects $1.8bn in 2024 revenue, driven by AI and Digital Health growth, and expanding imaging centers. Strong Q2 results with 13.9% revenue growth and 19.7% EBITDA increase, fueled by AI advancements and new imaging center openings. Future growth catalysts include market shifts to freestanding centers, increasing importance of joint ventures, and capital deployment for acquisitions and new facilities. Digital Health and AI initiatives, like DeepHealth OS and EBCD, are expected to drive significant revenue and margin expansion. Read the full article on Seeking AlphaAnalysis Article • Sep 22
Unpleasant Surprises Could Be In Store For RadNet, Inc.'s (NASDAQ:RDNT) Shares
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...
New Narrative • Aug 30
Expanding Imaging Modalities And AI Integration Signal Strong Future Growth In Healthcare Sector
Expansion into advanced imaging and integration of AI technologies aim at boosting revenue through higher reimbursement rates and operational efficiencies.Seeking Alpha • Aug 24
RadNet: Growth In Operating Earnings Off Very Little Incremental Capital
Summary RDNT stock is up 10% since my June publication following a strong set of quarterly numbers in its Q2 FY'24 earnings. Management continue executing on the growth route, recycling funds into new store openings. Same-store procedure volumes continue to ratchet higher, evidencing increased utilization of its legacy base. Net-net, reiterate buy. Read the full article on Seeking AlphaAnalysis Article • Jul 22
RadNet (NASDAQ:RDNT) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Jun 05
Returns On Capital At RadNet (NASDAQ:RDNT) Have Stalled
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...Seeking Alpha • Jun 05
RadNet: Qualified Growth Route, Still Undervalued
Summary RadNet, Inc. shares continue to show strength, having compounded by 184% since 2022. Q1 FY 2024 earnings showed growth in the Digital Health segment and increased MRI, CT, and PET/CT volumes. Management has increased its outlook on full-year revenues and projects $1.67-$1.7 billion in revenue for the year. Read the full article on Seeking AlphaAnalysis Article • May 10
Is There Now An Opportunity In RadNet, Inc. (NASDAQ:RDNT)?
While RadNet, Inc. ( NASDAQ:RDNT ) might not have the largest market cap around , it received a lot of attention from a...Analysis Article • Apr 08
Are RadNet, Inc. (NASDAQ:RDNT) Investors Paying Above The Intrinsic Value?
Key Insights Using the 2 Stage Free Cash Flow to Equity, RadNet fair value estimate is US$40.76 RadNet's US$49.04 share...Analysis Article • Mar 06
RadNet, Inc.'s (NASDAQ:RDNT) 26% Price Boost Is Out Of Tune With Revenues
The RadNet, Inc. ( NASDAQ:RDNT ) share price has done very well over the last month, posting an excellent gain of 26...Analysis Article • Feb 08
Why RadNet, Inc. (NASDAQ:RDNT) Could Be Worth Watching
RadNet, Inc. ( NASDAQ:RDNT ), might not be a large cap stock, but it received a lot of attention from a substantial...Seeking Alpha • Jan 28
RadNet, Inc. Stock Price Is More Vigorous Than Its Valuation
Summary RadNet, Inc. is assessed as a Buy opportunity especially on price dips for retail value investors; watch its valuation and growth ratings. The company's share price has seen significant growth recently but may drop due to volatility and potential missed estimates. RadNet is at the forefront of the movement to bring diagnostic imaging services out of hospitals, offering lower costs and increased accessibility. Read the full article on Seeking AlphaAnalysis Article • Dec 28
Getting In Cheap On RadNet, Inc. (NASDAQ:RDNT) Might Be Difficult
There wouldn't be many who think RadNet, Inc.'s ( NASDAQ:RDNT ) price-to-sales (or "P/S") ratio of 1.5x is worth a...Analysis Article • Dec 04
We Think RadNet (NASDAQ:RDNT) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Aug 27
RadNet (NASDAQ:RDNT) Might Be Having Difficulty Using Its Capital Effectively
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Analysis Article • Aug 09
RadNet (NASDAQ:RDNT) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Mar 30
We Think RadNet (NASDAQ:RDNT) Is Taking Some Risk With Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Feb 19
RadNet (NASDAQ:RDNT) Will Want To Turn Around Its Return Trends
There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...Shareholder Returns
| RDNT | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -0.1% | 2.7% | 2.2% |
| 1Y | 2.0% | 1.1% | 31.1% |
Return vs Industry: RDNT matched the US Healthcare industry which returned 1.1% over the past year.
Return vs Market: RDNT underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| RDNT volatility | |
|---|---|
| RDNT Average Weekly Movement | 6.6% |
| Healthcare Industry Average Movement | 7.8% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RDNT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RDNT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 9,060 | Howard Berger | www.radnet.com |
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.
RadNet, Inc. Fundamentals Summary
| RDNT fundamental statistics | |
|---|---|
| Market cap | US$4.55b |
| Earnings (TTM) | -US$14.19m |
| Revenue (TTM) | US$2.14b |
2.1x
P/S Ratio-320.9x
P/E RatioIs RDNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDNT income statement (TTM) | |
|---|---|
| Revenue | US$2.14b |
| Cost of Revenue | US$1.78b |
| Gross Profit | US$366.15m |
| Other Expenses | US$380.34m |
| Earnings | -US$14.19m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
May 11, 2026
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 17.07% |
| Net Profit Margin | -0.66% |
| Debt/Equity Ratio | 80.3% |
How did RDNT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 15:30 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RadNet, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sarah James | Barclays |
| Andrew Mok | Barclays |
| Yuan Zhi | B. Riley Securities, Inc. |